At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 229 enrolled
Drug / intervention
FF/UMEC/VI +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase IV, 12-week, Single Arm, Open Label Study Evaluating the Safety and Efficacy of Fixed Dose Triple Combination FF/UMEC/VI Administered Once Daily in the Morning Via a Dry Powder Inhaler in Participants With Chronic Obstructive Pulmonary Disease in India
In Brief
A Phase 4 clinical trial evaluating FF/UMEC/VI and ELLIPTA for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 229 participants across 14 sites.
Detailed Summary
This study will evaluate safety and efficacy of FF/UMEC/VI via ELLIPTA® inhaler. ELLIPTA is a registered trademark of GlaxoSmithKline group of companies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesIndia
Collaborators--
Timeline
Phase 4CompletedFinished
20222023202420252026
First PostedJun 2021
Enrollment StartJun 2023
Primary CompletionMar 2024
TodayJul 2026
First PostedJun 11, 2021
Enrollment StartJun 6, 2023
Primary CompletionMar 14, 2024
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 5.1 years ago
Interventions
FF/UMEC/VIdrug
FF/UMEC/VI will be administered
ELLIPTAdevice
Participants will receive FF/UMEC/VI using ELLIPTA inhaler.